Digital program plus an oral drug for Lewy body dementia
Part of Brain & nervous system, Mental health clinical trials.
This study tests an eHealth program together with a patient-and-caregiver support program, along with a medicine called ambroxol. It aims to see whether this combined approach is safe and helpful for people with dementia with Lewy bodies (or early memory changes from it).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 50 and 85 years old.
- You have a confirmed diagnosis of dementia with Lewy bodies (DLB) or DLB-related mild cognitive impairment (DLB-MCI).
- Your memory test score (MMSE) is 15 or higher.
- You can give informed consent and can follow study visits and instructions.
- You (or your caregiver) can take ambroxol by mouth every day for the full study period, as prescribed.
- You’re willing to provide blood samples for genetic testing (APOE and GBA).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether ambroxol (a mouth medicine) can help people with new or early dementia with Lewy bodies (DLB) or mild cognitive impairment linked to DLB. Participants take the medicine for about 18 months while the study tracks safety and changes over time.
This study tests a medicine called ambroxol, which may slow down the progression of Lewy body dementia. It aims to see if it can improve memory, thinking, and movement symptoms.
This study looks at how brain changes affect attention and thinking in people with Lewy body dementia. It includes brain scans, an EEG, and a medication option to see if it helps with symptoms.
This study is testing whether digital health tools (like wearable sensors) can better track symptoms of certain brain conditions (PSP, DLB, and MCI with Lewy bodies). It aims to improve monitoring and care for people with these conditions.
This trial tests a medicine normally used for high blood pressure (terazosin) to see if it can improve thinking or slow down decline in people with dementia with Lewy bodies. It's an early-stage study, so the goal is also to check safety.
This trial follows people with probable Lewy body dementia over several years to see how the brain changes on MRI and on memory/thinking tests. It may help researchers understand disease progression and improve future care for Lewy body dementia.
Hear when a new Dementia, Lewy Body trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.